SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-06-105169
Filing Date
2006-05-09
Accepted
2006-05-09 14:33:12
Documents
6
Period of Report
2006-05-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d8k.htm 8-K 15281
2 PRESS RELEASE DATED MAY 8, 2006 dex991.htm EX-99.1 9746
3 PRESS RELEASE DATED MAY 9, 2006 dex992.htm EX-99.2 12568
4 PRESS RELEASE DATED MAY 9, 2006 dex993.htm EX-99.3 16368
5 GRAPHIC g96563g965631.jpg GRAPHIC 14404
6 GRAPHIC g96563img_001.jpg GRAPHIC 7859
  Complete submission text file 0001193125-06-105169.txt   86574
Mailing Address 13950 BALLANTYNE CORPORATE PLACE UNIT 325 CHARLOTTE NC 28277
Business Address 13950 BALLANTYNE CORPORATE PLACE UNIT 325 CHARLOTTE NC 28277 704-341-1516
Chelsea Therapeutics International, Ltd. (Filer) CIK: 0001333763 (see all company filings)

IRS No.: 203174202 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51462 | Film No.: 06820218
SIC: 2836 Biological Products, (No Diagnostic Substances)